New oral diagnostic for celiac disease passes first safety check
NCT ID NCT07063823
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-stage study tested whether a single oral dose of HB-2121 is safe in adults. Researchers monitored 18 participants for side effects and tracked how the drug moves through the body over 30 days. The goal is to develop a new way to diagnose celiac disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test